Breaking News Instant updates and real-time market news.

KMPH

KemPharm

$0.21 /

+ (+0.00%)

08:48
06/18/20
06/18
08:48
06/18/20
08:48

KemPharm 'optimistic' about short-, long-term prospects

KemPharm announced that Travis Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company's 2020 Annual Meeting of Stockholders to be held on June 19, 2020. The letter provides an update on recent events and outlook for the remainder of 2020 and early 2021. "The last twelve months have been a period of significant advancement for KemPharm. While challenges certainly remain, there are also significant reasons for optimism. Just recently, the New Drug Application for KP415, our investigational product candidate for the treatment of attention deficit hyperactivity disorder, was successfully filed and accepted by the U.S. Food and Drug Administration. In addition, we recently received Day-74 Letter from the FDA which set the action date for KP415 as March 2, 2021. I am also pleased to pass along that there were no information requests included in the letter from the FDA that were not already expected, and the FDA informed us that an advisory committee is not required at this time. The FDA's acceptance of the KP415 NDA has triggered two important developments in our collaboration with Gurnet Point Capital and its affiliates. First, KemPharm earned and has since received the $5 million milestone payment as provided by the definitive collaboration and license agreement we entered into with an affiliate of GPC on September 3, 2019. Second, we were pleased to announce Corium, a GPC portfolio company, will lead all commercialization activities for KP415. Corium is led by several executives with significant experience in the commercialization of ADHD products, including its President and Chief Executive Officer, Perry Sternberg. Mr. Sternberg previously served a dual role at Shire as the Head of U.S. Commercial for seven therapeutic area business units, as well as the Chief Commercial Officer/Head of the Neuroscience Division, prior to the acquisition of Shire by Takeda Pharmaceutical Corporation Limited. During his tenure at Shire, Mr. Sternberg was responsible for bringing forth several groundbreaking ADHD products, including Vyvanse. Working with our existing debtholders, led by Deerfield Management, we were also able to complete an initial restructuring of our outstanding debt in December 2019, which allowed us to extend all principal and interest payments to a new maturity date of March 31, 2021, which is past the PDUFA date for KP415. This has extended our cash runway and allows us to capitalize on the opportunities that arise from the KP415/KP484 License Agreement and the potential approval of KP415 to negotiate a long-term restructure of our balance sheet. Based on these recent events and accomplishments, we are very optimistic about KemPharm's short- and long-term prospects. This enthusiasm is rooted in three core beliefs: KP415, if approved, has the potential to reshape the ADHD treatment landscape, particularly the methylphenidate product market; Corium possesses the most well-suited and experienced commercial organization to launch and maximize the potential market for KP415; and Addressing KemPharm's debt is an achievable goal."

  • 19

    Jun

  • 02

    Mar

KMPH KemPharm
$0.21 /

+ (+0.00%)

05/20/20 H.C. Wainwright
KemPharm price target lowered to $1.50 from $2.50 at H.C. Wainwright
09/05/19 H.C. Wainwright
H.C. Wainwright says KemPharm may have picked 'best possible' partner in GPC
09/05/19 Roth Capital
Roth Capital downgrades KemPharm to Neutral after Gurnet Point partnership
09/05/19 Roth Capital
KemPharm downgraded to Neutral from Buy at Roth Capital

TODAY'S FREE FLY STORIES

Conference/Events
Concrete Pumping management to meet virtually with DA Davidson » 10:42
07/13/20
07/13
10:42
07/13/20
10:42
BBCP

Concrete Pumping

$3.10 /

+0.01 (+0.32%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BBCP Concrete Pumping
$3.10 /

+0.01 (+0.32%)

BBCP Concrete Pumping
$3.10 /

+0.01 (+0.32%)

04/03/20 B. Riley FBR
Concrete Pumping downgraded on weakening markets at B. Riley FBR
04/03/20 B. Riley FBR
Concrete Pumping downgraded to Neutral from Buy at B. Riley FBR
03/24/20 Baird
Concrete Pumping downgraded to Neutral from at Baird
03/24/20 Baird
Concrete Pumping downgraded to Neutral from Outperform at Baird
BBCP Concrete Pumping
$3.10 /

+0.01 (+0.32%)

BBCP Concrete Pumping
$3.10 /

+0.01 (+0.32%)

Hot Stocks
Comtech awarded $54M contract for 911 technologies, services » 10:40
07/13/20
07/13
10:40
07/13/20
10:40
CMTL

Comtech

$15.08 /

-0.16 (-1.05%)

Comtech…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CMTL Comtech
$15.08 /

-0.16 (-1.05%)

CMTL Comtech
$15.08 /

-0.16 (-1.05%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
CMTL Comtech
$15.08 /

-0.16 (-1.05%)

CMTL Comtech
$15.08 /

-0.16 (-1.05%)

General news
FX Action: USD-CAD » 10:40
07/13/20
07/13
10:40
07/13/20
10:40

FX Action: USD-CAD…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
Shaw Communications price target raised to C$32 from C$31 at TD Securities » 10:35
07/13/20
07/13
10:35
07/13/20
10:35
SJR

Shaw Communications

$17.63 /

+1.08 (+6.53%)

TD Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SJR Shaw Communications
$17.63 /

+1.08 (+6.53%)

SJR Shaw Communications
$17.63 /

+1.08 (+6.53%)

07:35 Today Canaccord
Shaw Communications results beat as business remains solid, says Canaccord
06/03/20 Canaccord
Shaw Communications price target raised to C$26 from C$25 at Canaccord
06/02/20 National Bank
Shaw Communications price target raised to C$27 from C$26 at National Bank
04/13/20 Canaccord
Canaccord keeps Buy rating on Shaw after 'encouraging comments' in Q2 report
SJR Shaw Communications
$17.63 /

+1.08 (+6.53%)

SJR Shaw Communications
$17.63 /

+1.08 (+6.53%)

Recommendations
MTY Food Group price target raised to C$32 from C$29 at National Bank » 10:35
07/13/20
07/13
10:35
07/13/20
10:35
MTYFF

MTY Food Group

$0.00 /

+ (+0.00%)

National Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MTYFF MTY Food Group
$0.00 /

+ (+0.00%)

10:33 Today TD Securities
MTY Food Group price target raised to C$28 from C$24 at TD Securities
07:13 Today Veritas
MTY Food Group downgraded to Sell from Buy at Veritas
Options
KB Home put volume heavy and directionally bearish » 10:35
07/13/20
07/13
10:35
07/13/20
10:35
KBH

KB Home

$30.58 /

+0.045 (+0.15%)

Bearish flow noted in KB…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KBH KB Home
$30.58 /

+0.045 (+0.15%)

KBH KB Home
$30.58 /

+0.045 (+0.15%)

07:21 Today Seaport Global
Lennar downgraded to Neutral following outperformance at Seaport Global
07:17 Today Seaport Global
Seaport upgrades KB Home to Buy, sees some current headwinds becoming tailwinds
06:35 Today Seaport Global
KB Home upgraded to Buy from Neutral at Seaport Global
06/25/20
Fly Intel: Top five analyst downgrades
KBH KB Home
$30.58 /

+0.045 (+0.15%)

KBH KB Home
$30.58 /

+0.045 (+0.15%)

KBH KB Home
$30.58 /

+0.045 (+0.15%)

Hot Stocks
Bio Rad Laboratories trading resumes  10:34
07/13/20
07/13
10:34
07/13/20
10:34
 
Recommendations
MTY Food Group price target raised to C$28 from C$24 at TD Securities » 10:33
07/13/20
07/13
10:33
07/13/20
10:33
MTYFF

MTY Food Group

$0.00 /

+ (+0.00%)

TD Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MTYFF MTY Food Group
$0.00 /

+ (+0.00%)

07:13 Today Veritas
MTY Food Group downgraded to Sell from Buy at Veritas
Hot Stocks
A.O. Smith CIO Peter Martineau to retire, S. Melissa Scheppele to succeed » 10:32
07/13/20
07/13
10:32
07/13/20
10:32
AOS

A.O. Smith

$48.57 /

+0.315 (+0.65%)

, TGI

Triumph Group

$8.15 /

-0.1 (-1.21%)

A. O. Smith Corporation…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AOS A.O. Smith
$48.57 /

+0.315 (+0.65%)

TGI Triumph Group
$8.15 /

-0.1 (-1.21%)

AOS A.O. Smith
$48.57 /

+0.315 (+0.65%)

07/06/20 Northcoast
May water heater import decline due to Mexico, says Northcoast
05/29/20 UBS
A.O. Smith initiated with a Buy at UBS
05/06/20 Boenning & Scattergood
A.O. Smith upgraded to Outperform from Neutral at Boenning & Scattergood
04/02/20 Stifel
A.O. Smith initiated with a Buy at Stifel
TGI Triumph Group
$8.15 /

-0.1 (-1.21%)

03/20/20 BofA
BofA double downgrades Triumph, slashes price target amid COVID-19 impact
03/20/20 BofA
Triumph Group downgraded to Underperform from Buy at BofA
03/11/20 Goldman Sachs
Goldman cuts targets across Aerospace coverage for COVID-19 impact
08/23/19
Fly Intel: Top five analyst downgrades
AOS A.O. Smith
$48.57 /

+0.315 (+0.65%)

TGI Triumph Group
$8.15 /

-0.1 (-1.21%)

TGI Triumph Group
$8.15 /

-0.1 (-1.21%)

Hot Stocks
Bio Rad Laboratories trading halted, volatility trading pause  10:29
07/13/20
07/13
10:29
07/13/20
10:29
 
Conference/Events
Cantor Fitzgerald equity macro analysts hold analyst/industry conference call » 10:28
07/13/20
07/13
10:28
07/13/20
10:28

Analysts discuss equity…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
OncoSec participates in a webinar held by Alliance Global Partners » 10:25
07/13/20
07/13
10:25
07/13/20
10:25
ONCS

OncoSec

$2.35 /

+0.39 (+19.90%)

Biotech & Specialty…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ONCS OncoSec
$2.35 /

+0.39 (+19.90%)

ONCS OncoSec
$2.35 /

+0.39 (+19.90%)

12/16/19 Piper Jaffray
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Jaffray
Piper keeps Overweight on OncoSec after China Grand investment
Initiation
Cowen starts Royalty Pharma with Outperform, $55 price target » 10:22
07/13/20
07/13
10:22
07/13/20
10:22
RPRX

Royalty Pharma

$45.85 /

-1.7 (-3.58%)

Cowen analyst Steve Scala…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPRX Royalty Pharma
$45.85 /

-1.7 (-3.58%)

09:03 Today JPMorgan
Royalty Pharma initiated with a Neutral at JPMorgan
07:38 Today Morgan Stanley
Morgan Stanley starts Royalty Pharma at Equal Weight with $51 price target
07:14 Today SunTrust
Royalty Pharma initiated with a Buy at SunTrust
06:32 Today BofA
Royalty Pharma initiated with a Buy at BofA
  • 16
    Jun
RPRX Royalty Pharma
$45.85 /

-1.7 (-3.58%)

RPRX Royalty Pharma
$45.85 /

-1.7 (-3.58%)

Conference/Events
Wolfe Research financial analyst to hold an analyst/industry webcast » 10:21
07/13/20
07/13
10:21
07/13/20
10:21

Analysts, along with an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Options
Tesla and Apple dominate early single stock option volume as shares surge » 10:20
07/13/20
07/13
10:20
07/13/20
10:20
TSLA

Tesla

$1,721.19 /

+173.645 (+11.22%)

Tesla and Apple dominate…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$1,721.19 /

+173.645 (+11.22%)

TSLA Tesla
$1,721.19 /

+173.645 (+11.22%)

10:11 Today
Fly Intel: Top five analyst upgrades
08:53 Today Morgan Stanley
Morgan Stanley says Tesla's 'virtually unchallenged dominance' may be near end
08:03 Today Roth Capital
Tesla upgraded to Neutral at Roth Capital as Musk prepares Indian market entry
07:59 Today Roth Capital
Tesla upgraded to Neutral from Sell at Roth Capital
TSLA Tesla
$1,721.19 /

+173.645 (+11.22%)

  • 14
    Feb
TSLA Tesla
$1,721.19 /

+173.645 (+11.22%)

TSLA Tesla
$1,721.19 /

+173.645 (+11.22%)

TSLA Tesla
$1,721.19 /

+173.645 (+11.22%)

TSLA Tesla
$1,721.19 /

+173.645 (+11.22%)

Conference/Events
Wolfe Research multi-industry analyst to hold analyst/industry webcast » 10:19
07/13/20
07/13
10:19
07/13/20
10:19

Multi-Industry Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Initiation
Cowen starts Aimmune at Outperform, sees 'significant ramp' post COVID » 10:18
07/13/20
07/13
10:18
07/13/20
10:18
AIMT

Aimmune

$15.65 /

-0.02 (-0.13%)

, DBVT

DBV Technologies

$4.27 /

+0.08 (+1.91%)

Cowen analyst Boris…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AIMT Aimmune
$15.65 /

-0.02 (-0.13%)

DBVT DBV Technologies
$4.27 /

+0.08 (+1.91%)

AIMT Aimmune
$15.65 /

-0.02 (-0.13%)

10:11 Today
Fly Intel: Top five analyst initiations
06:16 Today Cowen
Aimmune initiated with an Outperform at Cowen
06/08/20 Piper Sandler
Piper Sandler remains bullish on Aimmune after updated data for Palforzia
05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
DBVT DBV Technologies
$4.27 /

+0.08 (+1.91%)

07/02/20 JMP Securities
JMP Securities positive on DBV Technologies' risk-reward
06/29/20 Citi
DBV approval likely to be delayed beyond action date, says Citi
06/29/20 H.C. Wainwright
DBV Technologies restructuring a proactive step, says H.C. Wainwright
06/26/20 Stifel
DBV restructuring 'not comforting for investors,' says Stifel
AIMT Aimmune
$15.65 /

-0.02 (-0.13%)

DBVT DBV Technologies
$4.27 /

+0.08 (+1.91%)

  • 30
    Jan
  • 09
    Oct
AIMT Aimmune
$15.65 /

-0.02 (-0.13%)

DBVT DBV Technologies
$4.27 /

+0.08 (+1.91%)

AIMT Aimmune
$15.65 /

-0.02 (-0.13%)

Technical Analysis
NASDAQ market internals summary » 10:17
07/13/20
07/13
10:17
07/13/20
10:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Conference/Events
Wolfe Research airlines analysts to hold an analyst/industry webcast » 10:17
07/13/20
07/13
10:17
07/13/20
10:17

Airlines Analysts provide…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Technical Analysis
NYSE market internals summary » 10:16
07/13/20
07/13
10:16
07/13/20
10:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

Upgrade
Cellular Biomedicine upgraded to Outperform following R&D Day at Baird » 10:15
07/13/20
07/13
10:15
07/13/20
10:15
CBMG

Cellular Biomedicine

$15.75 /

+0.86 (+5.78%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CBMG Cellular Biomedicine
$15.75 /

+0.86 (+5.78%)

10:02 Today Baird
Cellular Biomedicine upgraded to Outperform from Neutral at Baird
03/04/20 BTIG
Cellular Biomedicine downgraded to Neutral from Buy at BTIG
11/12/19 Baird
Cellular Biomedicine downgraded to Neutral at Baird
11/12/19 Baird
Cellular Biomedicine downgraded to Neutral from Outperform at Baird
CBMG Cellular Biomedicine
$15.75 /

+0.86 (+5.78%)

Options
GSX Techedu put volume heavy and directionally bearish » 10:15
07/13/20
07/13
10:15
07/13/20
10:15
GSX

GSX Techedu

$88.65 /

+0.915 (+1.04%)

Bearish flow noted in GSX…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GSX GSX Techedu
$88.65 /

+0.915 (+1.04%)

GSX GSX Techedu
$88.65 /

+0.915 (+1.04%)

07/01/20
Fly Intel: Top five analyst downgrades
06/30/20 Goldman Sachs
GSX Techedu downgraded to Neutral following outperformance at Goldman Sachs
06/30/20 Goldman Sachs
GSX Techedu downgraded to Neutral from Buy at Goldman Sachs
05/11/20 Barclays
GSX Techedu offered comprehensive rebuttal to short sellers, says Barclays
GSX GSX Techedu
$88.65 /

+0.915 (+1.04%)

  • 21
    Nov
GSX GSX Techedu
$88.65 /

+0.915 (+1.04%)

GSX GSX Techedu
$88.65 /

+0.915 (+1.04%)

GSX GSX Techedu
$88.65 /

+0.915 (+1.04%)

General news
Treasury Action: longer dated maturities are selling off » 10:15
07/13/20
07/13
10:15
07/13/20
10:15

Treasury Action: longer…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Wolfe Research energy analysts to hold a weekly analyst/industry webcast » 10:14
07/13/20
07/13
10:14
07/13/20
10:14

Integrated Oil Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Wolfe Research consumer goods/services to hold analyst/industry webcast » 10:11
07/13/20
07/13
10:11
07/13/20
10:11

Consumer Goods &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.